Leqembi OK’d as under-the-skin autoinjector for early Alzheimer’s
The U.S. Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb), an under-the-skin autoinjector formulation for maintenance dosing in early Alzheimer’s disease. The approval, announced by co-developers Biogen and Eisai, applies to those who first receive at least 1.5 years of the intravenous version. The approval…